Entrar Registro gratuito

ProMIS Neurosciences Propriedade de acionista maioritário

Qual é o Propriedade de acionista maioritário de ProMIS Neurosciences?

O Propriedade de acionista maioritário de ProMIS Neurosciences, Inc. é 5.01%

Qual é a definição de Propriedade de acionista maioritário?



A propriedade de acionistas maioritários é calculada como o número total de ações pertencentes aos acionistas maioritários (acionistas que possuem mais de 5% da corporação ou um executivo ou diretor da empresa) dividido pelo total de ações em circulação.

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

Propriedade de acionista maioritário de empresas na Setor Health Care em OTC em comparação com ProMIS Neurosciences

O que ProMIS Neurosciences faz?

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Empresas com propriedade de acionista maioritário semelhantes a ProMIS Neurosciences